555win cung cấp cho bạn một cách thuận tiện, an toàn và đáng tin cậy [xổ số miền nam thứ ba]
Jun 17, 2025 · Individuals may submit only one application as a PD/PI in response to this NOFO. Awards will be for $700,000 in direct costs per year, plus applicable Facilities and Administrative (F&A) costs. The project period is limited to five years.
Opportunity Number RFA-RM-25-001 Opportunity Title NIH Directors Pioneer Award Program (DP1 Clinical Trial Optional) Opportunity Category Discretionary Funding Instrument Type Grant Category of Funding Activity Health Expected Number of Awards CFDA Number (s) 93.310 -- Trans-NIH Research Support -- Cost Sharing or Matching Requirement No Read ...
Jun 17, 2025 · * Open to all career stages | Single-PI applications only | No preliminary data required | Must be new scientific research direction. * $700,000 direct costs per year for 5 years. Application deadline: September 9, 2025. For more information, visit: 600951.555win5win.com/pioneer.
Jan 17, 2025 · Learn about assistance programs, how to identify a potential funding organization, and past NIH funding. Take time to learn about each step in the grants process from planning to apply through developing and submitting your application to award and post-award reporting.
Applicants for the prize must have received their Ph.D. between January 1, 2023 and December 31, 2024. To enter the competition, applicants submit an essay based on their thesis.
Jun 13, 2025 · Read detailed information about this funding opportunity.
On 6/12/25 the National Institutes of Health posted grant opportunity RFA-RM-25-001 for NIH Directors Pioneer Award Program (DP1 Clinical Trial Optional). The grant will be issued under grant program 93.310 Trans-NIH Research Support.
3 days ago · When preparing an NIH application, proposers should review the specific solicitation and the NIH SF424 Application Guide. If human subjects are part of the project, use the NIH Human Subjects Decision Tool to:
Jun 13, 2025 · Request for Information (RFI): Better Tools to Predict Toxicities Resulting from Oligonucleotide Therapeutics (NOT-TR-25-011) National Center for Advancing Translational Sciences
Aug 11, 2025 · NIH Director’s Pioneer Award Program (DP1 Clinical Trial Optional) RFA-RM-25-001 Trailblazer Award for New and Early Stage Investigators (R21 Clinical Trial Optional) PA-25-169
Bài viết được đề xuất: